Bernhard Reis
Hoffmann-La Roche
21 Papers
35 Citations
Bernhard Reis is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Antigen & Cathepsin S. The author has an hindex of 9, co-authored 20 publications.
Chat about Author
Papers
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Stéphane Chevrier,Jacob H. Levine,Vito R T Zanotelli,Karina Silina,Daniel Schulz,Marina Bacac,Carola Ries,Laurie Ailles,Laurie Ailles,Michael A.S. Jewett,Holger Moch,Maries van den Broek,Christian Beisel,Michael B. Stadler,Michael B. Stadler,Craig Gedye,Bernhard Reis,Dana Pe'er,Bernd Bodenmiller +18 more
TL;DR: In this paper, the authors used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy controls.
934
Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression.
Florence Allantaz,Donavan T. Cheng,Tobias Bergauer,Palanikumar Ravindran,Michel F. Rossier,Martin Ebeling,Laura Badi,Bernhard Reis,Hans Bitter,Matilde D'Asaro,Alberto Chiappe,Sriram Sridhar,Gonzalo Durán Pacheco,Michael E. Burczynski,Denis F. Hochstrasser,Jacky Vonderscher,Thomas Matthes +16 more
TL;DR: The miRNA and mRNA expression profiles reported in this study form a comprehensive transcriptome database of various human blood cells and serve as a valuable resource for elucidating the role of miRNA mediated regulation in the establishment of immune cell identity.
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Carlos Gomez-Roca,Antoine Italiano,C. Le Tourneau,C. Le Tourneau,P. A. Cassier,Maud Toulmonde,Sandra P. D'Angelo,Sandra P. D'Angelo,M. Campone,Kristy L. Weber,Delphine Loirat,Michael A. Cannarile,Anna-Maria Jegg,Carola Ries,Randolph Christen,Georgina Meneses-Lorente,Wolfgang Jacob,Irina Klaman,Chia-Huey Ooi,Carl Watson,K. Wonde,Bernhard Reis,Francesca Michielin,Dominik Rüttinger,J.-P. Delord,J.-Y. Blay +25 more
TL;DR: Emactuzumab showed specific reduction of immunosuppressive TAMs at the OBD in both treatment arms but did not result in clinically relevant antitumor activity alone or in combination with paclitaxel.
162
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Oscar Puig,Bruno Daniele,Masatoshi Kudo,Philippe Merle,Joong-Won Park,Paul Ross,Jean-Marie Péron,Oliver Ebert,Stephen L. Chan,Tung Ping Poon,Massimo Colombo,Takuji Okusaka,Baek Yeol Ryoo,Beatriz Minguez,Takayoshi Tanaka,Toshihiko Ohtomo,Stacey Ukrainskyj,Frederic Boisserie,Olga Rutman,Ya Chi Chen,Chao Xu,Eliezer Shochat,Lori Jukofsky,Bernhard Reis,Gong Chen,Laura Di Laurenzio,Ray Lee,Chia Jui Yen +29 more
TL;DR: It was suggested though that a higher dose of codrituzumab or selecting patients with high level of glypican-3 or its mediator CD16 might improve outcome, as well as the use of CD16 and GPC3 as potential biomarkers would improve outcome.
109
Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
Bernhard Reis,Lori Jukofsky,Gong Chen,Giovanni Martinelli,Hua Zhong,W. Venus So,Michael Dickinson,Mark Drummond,Sarit Assouline,Maneja Hashemyan,Michel Theron,Steven Blotner,Je-Hwan Lee,Margaret Kasner,Sung-Soo Yoon,Ruediger Rueger,Karen Seiter,Steven A. Middleton,Kevin R. Kelly,Norbert Vey,Karen W.L. Yee,Gwen Nichols,Lin-Chi Chen,William E. Pierceall +23 more
TL;DR: In translational research described, biomarker expression by flow cytometry for MDM2 antagonist clinical response association in relapsed/refractory AML patients treated with idasanutlin-based therapy was investigated.